American Society of Hirudotherapy

Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management

Modified Delphi consensus study published in Critical care (London, England) (2026)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureJacobs R et al. · Critical care (London, England), 2026

Abstract

BACKGROUND: Regional citrate anticoagulation (RCA) is recommended by guidelines over systemic heparinization for continuous renal replacement therapy (CRRT). However, its use in patients with impaired citrate metabolism poses specific challenges and standardized guidance for managing RCA-related metabolic complications remains lacking. METHODS: A modified Delphi study was conducted according to a predefined protocol and reported in adherence with the CREDES (Conducting and REporting of DElphi Studies) checklist. The international expert panel comprised 29 clinicians and researchers from Europe, United States and Canada, with recognized expertise in RCA for CRRT in critically ill patients. Three iterative survey rounds were conducted to obtain agreement with proposed statements. RESULTS: Twenty-three experts completed all Delphi rounds, achieving consensus on twenty-two statements. RCA was considered feasible in patients with liver dysfunction, severe shock, or hyperlactatemia, with close monitoring and citrate dosing adjustment. Citrate accumulation can be prevented and managed using a stepwise approach, focused on reducing citrate delivery and discontinuing RCA in cases of overt accumulation. Metabolic alkalosis and electrolyte disturbances were identified as relevant but manageable complications, underscoring the need for individualizing CRRT settings. CONCLUSION: These consensus statements support the use of RCA during CRRT in critically ill patients with impaired citrate metabolism and provide practical guidance for monitoring and management of metabolic complications. However they reflect expert opinion, especially for questions with limited data and low-level evidence.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansContinuous Renal Replacement TherapyAnticoagulantsDelphi TechniqueCitric AcidConsensusSurveys and QuestionnairesMonitoring, PhysiologicRenal Replacement TherapyCritical Illness

Summary

Twenty-three experts completed a three-round Delphi and reached consensus on 22 statements supporting regional citrate anticoagulation for CRRT in critically ill patients, including those with liver dysfunction, with guidance for preventing citrate accumulation and managing alkalosis.

Context

This modified Delphi consensus convened an international panel (23 experts completing all rounds) and reached agreement on 22 statements about regional citrate anticoagulation (RCA) for continuous renal replacement therapy, concluding RCA is feasible even with impaired citrate metabolism given close monitoring and dose adjustment, and offering practical guidance on citrate accumulation and metabolic alkalosis. Citrate is an extracorporeal-circuit anticoagulant with a mechanism entirely unrelated to the leech secretome. This is expert-opinion consensus, not experimental data, and explicitly acknowledges low-level evidence for several statements. The document has no connection to leeches or hirudotherapy.

Citation

Reference (Vancouver style)

Jacobs R, Schneider A, Hoste E, Verbrugghe W, Bagshaw S, Bell M, et al. Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management. Crit Care. 2026;30(1):358. doi:10.1186/s13054-026-06066-x. PMID: 42129846

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.